A tiny Wall Street firm advising Pfizer on its giant deal has had an incredible year by Jonathan Marino on Nov 28, 2015, 9:15 AM Advertisement
 It has been a good year for Guggenheim Securities. The 16-year-old firm has been an adviser on five massive transactions in what has been one of the busiest years for mergers and acquisitions on record. Its biggest deal yet, Pfizer's $160 billion deal with Allergan, was announced on Monday. Guggenheim Securities is one of three boutiques advising Pfizer on the inversion deal. The others are Moelis and Co. and Centerview Partners. Goldman Sachs is also advising Pfizer on the deal. As the investment bank has expanded further into sectors that Wall Street's biggest banks count on for M&A revenue, it has also taken key talent from top advisers elsewhere in the investment-banking business. This includes Fares Noujaim, who was a star banker under Guggenheim executive chairman Alan Schwartz when they worked at Bear Stearns, and Jeff Hoffman and Joseph Kohls, healthcare-sector veterans from JPMorgan and Bank of America Merrill Lynch, respectively. Here is a breakdown of the 10 biggest deals for the bank, as tracked by the M&A data provider Dealogic — many of them from the past 12 months — that have increased Guggenheim's clout in the banking world. SEE ALSO: PFIZER CEO: 'This is a great deal for America' When Merck KGaA bought Millipore in 2010, it marked Guggenheim's biggest advisory role.  Sector: Pharmaceutical Deal: Big pharmaceutical deals have become a staple at Guggenheim Securities, and in 2010 its biggest mandate — in any sector — at the time was Merck KGaA's deal to acquire the Massachusetts-based life-sciences firm Millipore in a $7 billion transaction. Guggenheim and Perella Weinberg advised Merck on the deal.
Guggenheim dialed into profits when Verizon dealt select operations to Frontier Communications this year.  Sector: Telecommunications Deal: Guggenheim has been on both sides of big deals for Verizon. The boutique bank advised the telecom giant when it dealt wireline assets to Frontier Communications in a deal worth more than $10.5 billion to start 2015. Guggenheim worked alongside PJT Partners and Credit Suisse. The deal was announced in February.
Guggenheim helped Pfizer spin out its animal-health business, Zoetis.  Sector: Pharmaceutical Deal: In 2013, the pharmaceutical giant Pfizer was ready to part ways with its animal health and vaccine subsidiary, Zoetis. The initial public offering was announced in May 2013. The company, then valued at more than $14 billion, used Guggenheim and several other big Wall Street investment banks to spin the company out.
See the rest of the story at Business Insider
| 
0 comments:
Post a Comment